Published in Mol Ther on March 30, 2010
Retroviral integrations in gene therapy trials. Mol Ther (2012) 1.34
Gene therapy of chronic granulomatous disease: the engraftment dilemma. Mol Ther (2010) 1.34
Neonatal helper-dependent adenoviral vector gene therapy mediates correction of hemophilia A and tolerance to human factor VIII. Proc Natl Acad Sci U S A (2011) 1.11
Hepatic gene transfer in neonatal mice by adeno-associated virus serotype 8 vector. Hum Gene Ther (2012) 0.98
Lentiviral vectors for cancer immunotherapy and clinical applications. Cancers (Basel) (2013) 0.93
Impact of next-generation sequencing error on analysis of barcoded plasmid libraries of known complexity and sequence. Nucleic Acids Res (2014) 0.90
Preclinical evaluation of efficacy and safety of an improved lentiviral vector for the treatment of β-thalassemia and sickle cell disease. Curr Gene Ther (2015) 0.89
Correction of murine SCID-X1 by lentiviral gene therapy using a codon-optimized IL2RG gene and minimal pretransplant conditioning. Mol Ther (2011) 0.88
Mouse transplant models for evaluating the oncogenic risk of a self-inactivating XSCID lentiviral vector. PLoS One (2013) 0.85
Prospectives for gene therapy of retinal degenerations. Curr Genomics (2012) 0.83
Assessing the risk of T-cell malignancies in mouse models of SCID-X1. Mol Ther (2010) 0.82
Transduction of fetal mice with a feline lentiviral vector induces liver tumors which exhibit an E2F activation signature. Mol Ther (2013) 0.79
Lentiviral Engineered Fibroblasts Expressing Codon-Optimized COL7A1 Restore Anchoring Fibrils in RDEB. J Invest Dermatol (2016) 0.79
Gene Therapy for X-Linked Severe Combined Immunodeficiency: Where Do We Stand? Hum Gene Ther (2016) 0.79
Antiangiogenic and Neurogenic Activities of Sleeping Beauty-Mediated PEDF-Transfected RPE Cells In Vitro and In Vivo. Biomed Res Int (2015) 0.76
Limiting Thymic Precursor Supply Increases the Risk of Lymphoid Malignancy in Murine X-Linked Severe Combined Immunodeficiency. Mol Ther Nucleic Acids (2016) 0.75
A lentiviral gene therapy strategy for the in vitro production of feline erythropoietin. PLoS One (2012) 0.75
A novel intranuclear RNA vector system for long-term stem cell modification. Gene Ther (2015) 0.75
An international effort to cure a global health problem: A report on the 19th Hemoglobin Switching Conference. Exp Hematol (2015) 0.75
Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science (2000) 10.40
Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat Med (2006) 9.68
Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J Clin Invest (2008) 9.42
Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients. J Clin Invest (2008) 7.05
Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy. N Engl J Med (2002) 6.25
Gene transfer by lentiviral vectors is limited by nuclear translocation and rescued by HIV-1 pol sequences. Nat Genet (2000) 6.12
Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration. Nat Biotechnol (2006) 5.58
Gene therapy of X-linked severe combined immunodeficiency by use of a pseudotyped gammaretroviral vector. Lancet (2004) 5.43
Interleukin-2 receptor gamma chain: a functional component of the interleukin-7 receptor. Science (1993) 5.22
Gene therapy: therapeutic gene causing lymphoma. Nature (2006) 4.89
Hematopoietic stem-cell transplantation for the treatment of severe combined immunodeficiency. N Engl J Med (1999) 4.35
Defective IL7R expression in T(-)B(+)NK(+) severe combined immunodeficiency. Nat Genet (1998) 4.32
High-resolution insertion-site analysis by linear amplification-mediated PCR (LAM-PCR). Nat Methods (2007) 3.90
Long-term survival and transplantation of haemopoietic stem cells for immunodeficiencies: report of the European experience 1968-99. Lancet (2003) 3.44
The genotoxic potential of retroviral vectors is strongly modulated by vector design and integration site selection in a mouse model of HSC gene therapy. J Clin Invest (2009) 3.34
Activating Notch1 mutations in mouse models of T-ALL. Blood (2005) 3.08
Human severe combined immunodeficiency: genetic, phenotypic, and functional diversity in one hundred eight infants. J Pediatr (1997) 2.92
Cutting edge: the common gamma-chain is an indispensable subunit of the IL-21 receptor complex. J Immunol (2001) 2.69
Titering lentiviral vectors: comparison of DNA, RNA and marker expression methods. Gene Ther (2002) 2.59
Physiological promoters reduce the genotoxic risk of integrating gene vectors. Mol Ther (2008) 2.56
Lentiviral vectors for enhanced gene expression in human hematopoietic cells. Mol Ther (2000) 2.01
Equal potency of gammaretroviral and lentiviral SIN vectors for expression of O6-methylguanine-DNA methyltransferase in hematopoietic cells. Mol Ther (2005) 1.82
Globin lentiviral vector insertions can perturb the expression of endogenous genes in beta-thalassemic hematopoietic cells. Mol Ther (2008) 1.78
Mutation at the polymerase active site of mouse DNA polymerase delta increases genomic instability and accelerates tumorigenesis. Mol Cell Biol (2007) 1.74
Unique risk factors for insertional mutagenesis in a mouse model of XSCID gene therapy. Proc Natl Acad Sci U S A (2006) 1.67
Promoter trapping reveals significant differences in integration site selection between MLV and HIV vectors in primary hematopoietic cells. Blood (2004) 1.53
Self-inactivating gammaretroviral vectors for gene therapy of X-linked severe combined immunodeficiency. Mol Ther (2008) 1.44
Ectopic retroviral expression of LMO2, but not IL2Rgamma, blocks human T-cell development from CD34+ cells: implications for leukemogenesis in gene therapy. Leukemia (2007) 1.43
The common gamma-chain for multiple cytokine receptors. Adv Immunol (1995) 1.38
Dose finding with retroviral vectors: correlation of retroviral vector copy numbers in single cells with gene transfer efficiency in a cell population. Blood (2003) 1.34
High throughput detection of retrovirus-associated reverse transcriptase using an improved fluorescent product enhanced reverse transcriptase assay and its comparison to conventional detection methods. J Virol Methods (1999) 1.17
Predictable and efficient retroviral gene transfer into murine bone marrow repopulating cells using a defined vector dose. Exp Hematol (2003) 1.16
A rapid and quantitative assay for measuring neighboring gene activation by vector proviruses. Mol Ther (2008) 1.15
Longitudinal assessment of hematopoietic abnormalities after autologous hematopoietic cell transplantation for lymphoma. J Clin Oncol (2005) 1.06
Ex vivo gene therapy with lentiviral vectors rescues adenosine deaminase (ADA)-deficient mice and corrects their immune and metabolic defects. Blood (2006) 1.04
Clonal haemopoiesis may occur after conventional chemotherapy and is associated with accelerated telomere shortening and defects in the NQO1 pathway; possible mechanisms leading to an increased risk of t-AML/MDS. Br J Haematol (2004) 1.00
Promoter interference mediated by the U3 region in early-generation HIV-1-derived lentivirus vectors can influence detection of transgene expression in a cell-type and species-specific manner. Hum Gene Ther (2003) 0.97
Murine retroviral but not human cellular promoters induce in vivo erythroid-specific deregulation that can be partially prevented by insulators. Mol Ther (2007) 0.95
Importance of murine study design for testing toxicity of retroviral vectors in support of phase I trials. Mol Ther (2007) 0.94
A novel model of SCID-X1 reconstitution reveals predisposition to retrovirus-induced lymphoma but no evidence of gammaC gene oncogenicity. Mol Ther (2009) 0.93
Stable and functional lymphoid reconstitution in artemis-deficient mice following lentiviral artemis gene transfer into hematopoietic stem cells. Mol Ther (2008) 0.91
Restoration of lymphoid populations in a murine model of X-linked severe combined immunodeficiency by a gene-therapy approach. Blood (1999) 0.90
Transduced CD34+ cells from adrenoleukodystrophy patients with HIV-derived vector mediate long-term engraftment of NOD/SCID mice. Mol Ther (2003) 0.89
Limiting {gamma}c expression differentially affects signaling via the interleukin (IL)-7 and IL-15 receptors. Blood (2007) 0.83
Long-term cardiac allograft survival across an MHC mismatch after "pruning" of alloreactive CD4 T cells. J Immunol (2008) 0.80
T cell receptor BV repertoires using real time PCR: a comparison of SYBR green and a dual-labelled HuTrec fluorescent probe. J Immunol Methods (2004) 0.80
Murine leukemia following irradiation conditioning for transplantation of lentivirally-modified hematopoietic stem cells. Eur J Haematol (2007) 0.78
Notch1 is a frequent mutational target in chemically induced lymphoma in mouse. Int J Cancer (2008) 0.77
Origins and functional impact of copy number variation in the human genome. Nature (2009) 23.63
Effect of gene therapy on visual function in Leber's congenital amaurosis. N Engl J Med (2008) 15.30
Molecular definition of breast tumor heterogeneity. Cancer Cell (2007) 12.67
A systematic survey of loss-of-function variants in human protein-coding genes. Science (2012) 12.25
Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat Med (2006) 9.68
Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J Clin Invest (2008) 9.42
Molecular characterization of the tumor microenvironment in breast cancer. Cancer Cell (2004) 9.41
Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy. Science (2009) 8.80
A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N Engl J Med (2003) 8.59
Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells. J Exp Med (2006) 8.41
Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients. J Clin Invest (2008) 7.05
Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy. N Engl J Med (2002) 6.25
Gene therapy of X-linked severe combined immunodeficiency by use of a pseudotyped gammaretroviral vector. Lancet (2004) 5.43
PPM1A functions as a Smad phosphatase to terminate TGFbeta signaling. Cell (2006) 5.28
TLR4 activation mediates kidney ischemia/reperfusion injury. J Clin Invest (2007) 4.77
Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease. Nat Med (2010) 4.76
Long-term exposure of E-mu-Pim1 transgenic mice to 898.4 MHz microwaves does not increase lymphoma incidence. Radiat Res (2002) 4.16
Interferon gamma is required for activation-induced death of T lymphocytes. J Exp Med (2002) 3.80
Efficacy of gene therapy for X-linked severe combined immunodeficiency. N Engl J Med (2010) 3.54
Association between changes in air pollution levels during the Beijing Olympics and biomarkers of inflammation and thrombosis in healthy young adults. JAMA (2012) 3.52
Long-term survival and transplantation of haemopoietic stem cells for immunodeficiencies: report of the European experience 1968-99. Lancet (2003) 3.44
No evidence of clonal somatic genetic alterations in cancer-associated fibroblasts from human breast and ovarian carcinomas. Nat Genet (2008) 3.32
Rejection of the kidney allograft. N Engl J Med (2010) 3.30
Vector integration is nonrandom and clustered and influences the fate of lymphopoiesis in SCID-X1 gene therapy. J Clin Invest (2007) 3.28
Allogeneic bone marrow transplantation in mevalonic aciduria. N Engl J Med (2007) 3.18
A robust model for read count data in exome sequencing experiments and implications for copy number variant calling. Bioinformatics (2012) 3.10
Cell type-specific DNA methylation patterns in the human breast. Proc Natl Acad Sci U S A (2008) 2.99
Gammaretrovirus-mediated correction of SCID-X1 is associated with skewed vector integration site distribution in vivo. J Clin Invest (2007) 2.80
Essential role of the NADPH oxidase subunit p47(phox) in endothelial cell superoxide production in response to phorbol ester and tumor necrosis factor-alpha. Circ Res (2002) 2.79
Hot spots of retroviral integration in human CD34+ hematopoietic cells. Blood (2007) 2.79
Structural insights into the regulatory particle of the proteasome from Methanocaldococcus jannaschii. Mol Cell (2009) 2.75
Effective gene therapy with nonintegrating lentiviral vectors. Nat Med (2006) 2.70
DNA bar coding and pyrosequencing to analyze adverse events in therapeutic gene transfer. Nucleic Acids Res (2008) 2.64
New ISSCR guidelines underscore major principles for responsible translational stem cell research. Cell Stem Cell (2008) 2.61
Estrogens protect pancreatic beta-cells from apoptosis and prevent insulin-deficient diabetes mellitus in mice. Proc Natl Acad Sci U S A (2006) 2.59
Gene therapy clinical trials worldwide to 2012 - an update. J Gene Med (2013) 2.57
Insertional transformation of hematopoietic cells by self-inactivating lentiviral and gammaretroviral vectors. Mol Ther (2009) 2.56
Principal axis-based correspondence between multiple cameras for people tracking. IEEE Trans Pattern Anal Mach Intell (2006) 2.47
An intraductal human-in-mouse transplantation model mimics the subtypes of ductal carcinoma in situ. Breast Cancer Res (2009) 2.37
Transplantation of hematopoietic stem cells and long-term survival for primary immunodeficiencies in Europe: entering a new century, do we do better? J Allergy Clin Immunol (2010) 2.35
The Wiskott-Aldrich syndrome. J Allergy Clin Immunol (2006) 2.29
Persistence of naive CD45RA+ regulatory T cells in adult life. Blood (2005) 2.27
Clinical features and outcome of patients with IRAK-4 and MyD88 deficiency. Medicine (Baltimore) (2010) 2.26
Bone marrow failure in Fanconi anemia is triggered by an exacerbated p53/p21 DNA damage response that impairs hematopoietic stem and progenitor cells. Cell Stem Cell (2012) 2.26
Chimerism and tolerance in a recipient of a deceased-donor liver transplant. N Engl J Med (2008) 2.22
Immune reconstitution without graft-versus-host disease after haemopoietic stem-cell transplantation: a phase 1/2 study. Lancet (2002) 2.21
Comprehensive genomic access to vector integration in clinical gene therapy. Nat Med (2009) 2.19
A heterozygous moth genome provides insights into herbivory and detoxification. Nat Genet (2013) 2.13
Successful reconstitution of immunity in ADA-SCID by stem cell gene therapy following cessation of PEG-ADA and use of mild preconditioning. Mol Ther (2006) 2.08
Dynamics of gene-modified progenitor cells analyzed by tracking retroviral integration sites in a human SCID-X1 gene therapy trial. Blood (2010) 2.05
Long-term outcome after hematopoietic stem cell transplantation of a single-center cohort of 90 patients with severe combined immunodeficiency. Blood (2009) 2.03
Nucleation and growth of nanoparticles in the atmosphere. Chem Rev (2011) 1.99
Autoimmunity in Wiskott-Aldrich syndrome: risk factors, clinical features, and outcome in a single-center cohort of 55 patients. Pediatrics (2003) 1.91
Do myoepithelial cells hold the key for breast tumor progression? J Mammary Gland Biol Neoplasia (2005) 1.91
Outcomes of transplantation using various hematopoietic cell sources in children with Hurler syndrome after myeloablative conditioning. Blood (2013) 1.91
BRAF inhibitor resistance mechanisms in metastatic melanoma: spectrum and clinical impact. Clin Cancer Res (2014) 1.89
Fibroblasts can be genetically modified to produce excitable cells capable of electrical coupling. Circulation (2005) 1.87
Stable gene transfer to muscle using non-integrating lentiviral vectors. Mol Ther (2007) 1.81
Long-term persistence of a polyclonal T cell repertoire after gene therapy for X-linked severe combined immunodeficiency. Sci Transl Med (2011) 1.81
Hematopoietic stem cell gene therapy for adenosine deaminase-deficient severe combined immunodeficiency leads to long-term immunological recovery and metabolic correction. Sci Transl Med (2011) 1.81
Two novel activating mutations in the Wiskott-Aldrich syndrome protein result in congenital neutropenia. Blood (2006) 1.80
Outcome of hematopoietic stem cell transplantation for adenosine deaminase-deficient severe combined immunodeficiency. Blood (2012) 1.80
The cytoplasm of living cells behaves as a poroelastic material. Nat Mater (2013) 1.80
Global chromatin profiling reveals NSD2 mutations in pediatric acute lymphoblastic leukemia. Nat Genet (2013) 1.77
Disruption of E-cadherin by matrix metalloproteinase directly mediates epithelial-mesenchymal transition downstream of transforming growth factor-beta1 in renal tubular epithelial cells. Am J Pathol (2009) 1.75
Glutamine sensitivity analysis identifies the xCT antiporter as a common triple-negative breast tumor therapeutic target. Cancer Cell (2013) 1.73
Gene delivery to the juvenile mouse liver using AAV2/8 vectors. Mol Ther (2008) 1.73
CD4+CD25+ regulatory T cells protect against injury in an innate murine model of chronic kidney disease. J Am Soc Nephrol (2006) 1.72
The leukocyte podosome. Eur J Cell Biol (2005) 1.72
Codon optimization of human factor VIII cDNAs leads to high-level expression. Blood (2010) 1.68
Depletion of gammadelta T cells exacerbates murine adriamycin nephropathy. J Am Soc Nephrol (2007) 1.68
Cytoskeletal remodeling mediated by WASp in dendritic cells is necessary for normal immune synapse formation and T-cell priming. Blood (2011) 1.67
A hypomorphic R229Q Rag2 mouse mutant recapitulates human Omenn syndrome. J Clin Invest (2007) 1.67
Early posttransplantation donor-derived invariant natural killer T-cell recovery predicts the occurrence of acute graft-versus-host disease and overall survival. Blood (2012) 1.65
Megakaryocytes assemble podosomes that degrade matrix and protrude through basement membrane. Blood (2013) 1.65
Single-strand conformation polymorphism (SSCP) for the analysis of genetic variation. Nat Protoc (2006) 1.64
Transgenic mice overexpressing BMP4 develop a fibrodysplasia ossificans progressiva (FOP)-like phenotype. Am J Pathol (2004) 1.60
LIF and BMP signaling generate separate and discrete types of GFAP-expressing cells. Development (2005) 1.59
The presence of FGF2 signaling determines whether beta-catenin exerts effects on proliferation or neuronal differentiation of neural stem cells. Dev Biol (2004) 1.59
Structural basis of EZH2 recognition by EED. Structure (2007) 1.58
Gene therapy: X-SCID transgene leukaemogenicity. Nature (2006) 1.57
Wiskott-Aldrich syndrome protein deficiency leads to reduced B-cell adhesion, migration, and homing, and a delayed humoral immune response. Blood (2004) 1.56
Characteristics and outcome of early-onset, severe forms of Wiskott-Aldrich syndrome. Blood (2012) 1.56
Deficiency in the Wiskott-Aldrich protein induces premature proplatelet formation and platelet production in the bone marrow compartment. Blood (2006) 1.56
Approaching the promise of operational tolerance in clinical transplantation. Transplantation (2011) 1.54
A ubiquitous chromatin opening element (UCOE) confers resistance to DNA methylation-mediated silencing of lentiviral vectors. Mol Ther (2010) 1.54
Diminished production of anti-inflammatory mediators during neutrophil apoptosis and macrophage phagocytosis in chronic granulomatous disease (CGD). J Leukoc Biol (2003) 1.53
X-linked thrombocytopenia (XLT) due to WAS mutations: clinical characteristics, long-term outcome, and treatment options. Blood (2010) 1.51
Autoimmune lymphoproliferative syndrome: molecular basis of disease and clinical phenotype. Br J Haematol (2006) 1.49
Unregulated actin polymerization by WASp causes defects of mitosis and cytokinesis in X-linked neutropenia. J Exp Med (2007) 1.49